Global Multiple Sclerosis Therapies Market, Type (Immunosuppressants, Immunomodulators) Route of Administration (Oral, Injectable, Intravenous), End User (Hospital and Clinics, Diagnostic Laboratories, Others) – Industry Trends and Forecast to 2030.
Multiple Sclerosis Therapies Market Analysis and Size
The increasing burden of different infectious diseases on the global healthcare system is a main consideration, with emerging countries bearing a disproportionate share of the burden. As per the Institute of Liver and Biliary Sciences India, about 3% of the world's population is hugely infected with the hepatitis C virus. The global increase in the occurrence of HCV infections, particularly both in developed and developing countries is a primary factor leading to the growth of the global multiple sclerosis therapies market.
Data Bridge Market Research analyses that the multiple sclerosis therapies market is expected to reach USD 38.33 million by 2030, which is USD 25.75 million in 2022, and is expected to undergo a CAGR of 5.10% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Multiple Sclerosis Therapies Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Immunosuppressants, Immunomodulators) Route of Administration (Oral, Injectable, Intravenous), End User (Hospitals, Trauma Centres, Ambulatory Surgical Centres and Other)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Biora Therapeutics, Inc (U.S.), Boehringer Ingelheim International Gmbh (Germany), Amgen Inc. (U.S.), Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Novartis AG (Switzerland)., Bayer AG (Germany), Bristol Myers Squibb Company (U.S.), Biogen (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc (U.K.), Abbott (U.S.), Bio-Rad Laboratories Inc. (U.S.), Mylan N.V. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Multiple sclerosis (MS) is a chronic and inflammatory immune-mediated condition that can cause axonal transection, demyelination, and neurodegeneration of the spinal cord and brain nerve cells. Some of the frequently used therapies include the administration of injectable, oral and infused medicines, antidepressants, physical therapy and muscle relaxants.
Multiple Sclerosis Therapies Market Dynamics
Drivers
- Increasing Incidence of Multiple Sclerosis
There has been increasing occurrences of multiple sclerosis globally. According to the National Multiple Sclerosis Society’s study, around 1 million adults were suffering with multiple sclerosis in the U.S. in 2017. An estimated incidence of the disease was around 309 cases per 100,000 people in 2010, resulting in total of 727,344 multiple sclerosis cases among adults. According to the Government of Canada, more than 77,000 Canadians were surviving with multiple sclerosis of which 3/4th were women. The Multiple Sclerosis Society stated that about 110,000 people were suffering from the condition in the UK in 2018. It is also observed that MS is more than twice incident in females. The number of new patients diagnosed every year is also growing, which means that the number rise from 5,000 patients in 2017 to 6,700 in 2018. Thus, this incidence rate is boosting the demand for the treatment drugs.
Opportunities
- Increased R&D Activities by Organizations
Numerous drugs are in the research phase for the treatment of multiple sclerosis (MS) and many are undergoing clinical trials. U.S. FDA has approved several drugs for treating MS, namely fingolimod, interferons, natalizumab, glatiramer acetate, teriflunomide, and dimethyl fumarate. Several geneticists as well as other researchers are studying human genome for causes and other possible treatments for diseases such as muscular dystrophy, Alzheimer's, cancer and diabetes. For instance, they have found that some people with a specific gene are more likely to develop Alzheimer's disease. So researchers are now working on drugs that will modify or repair that particular gene. Likewise, many researchers have found that some people suffering from multiple sclerosis have a certain gene, making them more vulnerable to the disease. Hence, they are now consistently working on drugs that will either alter or repair that gene.
Restraints/Challenges
- High cost of Drugs
The cost of multiple sclerosis drugs remains a constant challenge to the market growth despite of the high prevalence of multiple sclerosis. The high pricing of drugs makes it inefficient to meet the needs pf the affected population. DMTs are the standard option for treatment but the extreme cost of these drugs leads to the improper adherence and disease management. As per the National Multiple Sclerois Society, the cost of MS drugs are increasing hugely. This factor is anticipated to limit the market growth.
This multiple sclerosis therapies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the multiple sclerosis therapies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments:
- In 2021, Janssen received U.S. FDA approval for Ponvory. It is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator used to treat adults with relapsing forms of multiple sclerosis (MS), such as clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
- In 2020, Novartis announced the US FDA approval for Kesimpta® in the form of an injection for subcutaneous use for treating the relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Global Multiple Sclerosis Therapies Market Scope
The multiple sclerosis therapies market is segmented on the basis of type, route of administration and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Immunosuppressants
- Humira
- Infliximab
- Immunomodulators
- Thalidomide
- Lenalidomide
Route of Administration
- Oral
- Injectable
- Intravenous
End-User
- Hospital and Clinics
- Diagnostic Laboratories
- Others
Multiple Sclerosis Therapies Regional Analysis/Insights
The multiple sclerosis therapies market is analyzed and market size insights and trends are provided by type, route of administration and end-user as referenced above.
The countries covered in the multiple sclerosis therapies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the multiple sclerosis therapies market because of the strong demand for the multiple sclerosis drugs and increase in U.S. FDA approvals for medicines used in treating multiple sclerosis and improved healthcare system in this region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the improved pharmaceutical networks and initiatives to reduce costs in several regions .
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The multiple sclerosis therapies market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for multiple sclerosis therapies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the multiple sclerosis therapies market. The data is available for historic period 2011-2021.
Competitive Landscape and Global Multiple Sclerosis Therapies Market Share Analysis
The multiple sclerosis therapies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to multiple sclerosis therapies market.
Some of the major players operating in the multiple sclerosis therapies market are:
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Biora Therapeutics, Inc (U.S.)
- Boehringer Ingelheim International Gmbh (Germany)
- Amgen Inc. (U.S.)
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Bristol Myers Squibb Company (U.S.)
- Biogen (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Takeda Pharmaceutical Company Limited (Japan)
- Jazz Pharmaceuticals, Inc (U.K.)
- Abbott (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- Mylan N.V. (U.S.)
SKU-